NMPA Approval

Basiliximab for Injection

Approval Number

国药准字SJ20171040

Registration Date

April 27, 2022

Previous Approval Numbers

S20171040

Drug Information

Generic Name

注射用巴利昔单抗

Trade Name

舒莱

Dosage Form

注射剂

Strength

20mg/瓶

Drug Type

生物制品

Registration Date

April 27, 2022

Expiry Date

April 26, 2027

Company Address

6343 Risch, Switzerland

Company Address

Schaffhauserstrasse 4332 Stein, Switzerland

Empowering clinical research with data-driven insights and AI-powered tools.

注射用巴利昔单抗 - NMPA 批准文号 | MedPath